Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Monday, June 1, 2009 - 09:35
in Health & Medicine
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.